MAPT and Alzheimer disease: APOE4 carrier status is associated with increased risk of AD through amyloid - and tau-dependent and independent pathways, such as increased neuroinflammation (Burt et al., 2008; Wang et al., 2022), disruption of glucose and lipid metabolism, causing oxidative stress, and reduced neurovascular integrity (Yamazaki et al., 2019).